OOIR: Observatory of International Research

Papers

(The TQCC of European Journal of Health Economics is 7. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-08-01 to 2025-08-01.)

Article	Citations
Education and medication use later in life and the role of intelligence	72
Beyond 10-year lead-times in EQ-5D-5L: leveraging alternative lead-times in willingness-to-accept questions to capture preferences for worse-than-dead states and their implication	67
Costing methodologies in European economic evaluation guidelines: commonalities and divergences	59
Should Scotland provide genome-wide sequencing for the diagnosis of rare developmental disorders? A cost-effectiveness analysis	55
Cost-effectiveness of adding oseltamivir to primary care for influenza-like-illness: economic evaluation alongside the randomised controlled ALIC4E trial in 15 European countries	55
Correction to: Geographic distribution of physicians in Portugal	44
Characteristics and health care costs in patients with a diagnostic imaging for low back pain in Switzerland	40
Psychometric properties and general population reference values for PROMIS Global Health in Hungary	39
Pragmatic randomized controlled trial comparing a complex telemedicine-based intervention with usual care in patients with chronic conditions	34
Comparing the measurement properties of the EQ-5D-Y-3L, EQ-5D-Y-5L and CHU9D in children and adolescents: a measurement property study	32
The hidden cost of sophistication: economic complexity and obesity	31
Patient-level cost analysis of subfertility pathways in the Dutch healthcare system	28
Cost-effectiveness and budget impact of venetoclax in combination with rituximab in relapsed/refractory chronic lymphocytic leukemia in Switzerland	28
Cost-effectiveness of transcatheter aortic valve implantation in patients at low surgical risk in France: a model-based analysis of the Evolut LR trial	28
Prescription opioids and economic hardship in France	26
Comparative cost-effectiveness of nivolumab first-line and second-line therapy for advanced esophageal cancer in Japan	25
Cost awareness among intensivists in their daily clinical practice: a prospective multicentre study	24
Cost-effectiveness analysis of vaborem for the treatment of carbapenem-resistant Enterobacteriaceae-Klebsiella pneumoniae carbapenemase (CRE-KPC) infections in the UK	23
The employment situation of people living with HIV: a closer look at the effects of the 2008 economic crisis	23
Workload and short sickness absences in a cohort of Finnish hospital employees	23
From test to rest: evaluating socioeconomic differences along the COVID-19 care pathway in the Netherlands	22
Expensive today but cheaper tomorrow: lifetime costs of an active middle ear implant compared to alternative treatment options	22
Setting incentives right with long-term risk adjustment	21
Primary care services and emergency department visits in blended fee-for-service and blended capitation models: evidence from Ontario, Canada	21
Nothing about us, without us? A reflection on and call for involving children in the process of valuing child health	21

Health-related quality of life in patients with alcohol use disorder: comparing instruments and mapping from clinical measures to preference-based measures	19
Economic assessment of abemaciclib for the adjuvant treatment of luminal HER2- breast cancer from the perspective of the Spanish health system	19
Cost-effectiveness of encorafenib with binimetinib in unresectable or metastatic BRAF-mutant melanoma	19
The costs of celiac disease: a contingent valuation in Switzerland	18
The causal effect of catastrophic health expenditure on poverty in Poland	18
On spillovers in economic evaluations: definition, mapping review and research agenda	18
Trends in NICE technology appraisals of non-small cell lung cancer drugs over the last decade	18
The EORTC QLU-C10D is a valid cancer-specific preference-based measure for cost-utility and health technology assessment in the Netherlands	18
Hospital resource utilisation from HPV-related diseases in England: a real-world cost analysis	17
Generating EQ-5D-5L health utility scores from BASDAI and BASFI: a mapping study in patients with axial spondyloarthritis using longitudinal UK registry data	17
Correction: AOTMiT reimbursement recommendations compared to other HTA agencies	17
Breaking the rules: decision-making under absolute resource constraints	17
Antivirals to prepare for surges in influenza cases: an economic evaluation of baloxavir marboxil for the Netherlands	17
Can competition improve hospital quality of care? A difference-in-differences approach to evaluate the effect of increasing quality transparency on hospital quality	16
How perceptions of bone marrow donation costs affect donation behavior: survey evidence from a large donor registry	16
Analyzing nurses’ decisions to leave their profession—a duration analysis	16
The trade-off between health system resiliency and efficiency: evidence from COVID-19 in European regions	16
Benefits beyond health in the willingness to pay for a quality-adjusted life-year	16
Measuring health-related quality of life and well-being: a head-to-head psychometric comparison of the EQ-5D-5L, ReQoL-UI and ICECAP-A	15
The social value of gambling: surplus estimates by gambling types for France	15
The impacts of working from home on individual health and well-being	15
A principled approach to non-discrimination in cost-effectiveness	15
Estimating loss in capability wellbeing in the first year of the COVID-19 pandemic: a cross-sectional study of the general adult population in the UK, Australia and the Netherlands	15
Costs attributable to hypercholesterolemia in a single period and over the life cycle	15
The impact on quality of life of diet restrictions and disease symptoms associated with phenylketonuria: a time trade-off and discrete choice experiment study	14
The goal of risk equalization in regulated competitive health insurance markets	14
Is ultra-hypo-fractionated radiotherapy more cost-effective relative to conventional fractionation in treatment of prostate cancer? A cost–utility analysis alongside a randomized HYPO-RT-PC trial	14
Economic value of diastasis repair with the use of mesh compared to no intervention in Italy	14
Time value of informal care of people with alzheimer’s disease in Spain: a population-based analysis	14
Sex differences in care complexity and cost of cardiac-related procedures as a basis for improving hospital payments systems	14
Machine learning versus regression modelling in predicting individual healthcare costs from a representative sample of the nationwide claims database in France	13
Adverse selection and consumer inertia: empirical evidence from the Dutch health insurance market	13
Does prescribing apixaban or rivaroxaban versus warfarin for patients diagnosed with atrial fibrillation save health system costs? A multivalued treatment effects analysis	13
The impact of ambulatory care spending, continuity and processes of care on ambulatory care sensitive hospitalizations	13
Does medial tourism promote growth in healthcare sector?	12
Valuation of the EQ-5D-3L in Jordan	12
Do mobile hospital teams in residential aged care facilities increase health care efficiency: an evaluation of French residential care policy	12
Modeling European health systems: an ideal chain of services	12
The attractiveness of jobs in the German care sector: results of a factorial survey	12
Pharmacy cost groups for the German morbidity-based risk compensation scheme	12
A comprehensive review of official discount rates in guidelines of health economic evaluations over time: the trends and roots	12
Work ethics, stay-at-home measures and COVID-19 diffusion	12
Scales and size-quality outcomes in adult learning disability residential care: evidence from the UK	11
Do we care about high-cost patients? Estimating the savings on health spending by integrated care	11
Validation of the PAM-13 instrument in the Hungarian general population 40 years old and above	11
Alcohol prices, the April effect, and the environment, in violence-related injury in England and Wales	11
Preferences for COVID-19 epidemic control measures among French adults: a discrete choice experiment	11
Tenders for generics and biosimilars: a challenging purchasing policy	11
Infections, accidents and nursing overtime in a neonatal intensive care unit	11
Changes in spending, quality indicators, and provider experiences following the introduction of a population-based payment model in dutch primary care: a mixed methods evaluation	11

Significant healthcare burden and life cost of spinal muscular atrophy: real-world data	10
The effect of mental and physical health problems on sickness absence	10
Modeling the potential efficiency of a blood biomarker-based tool to guide pre-hospital thrombolytic therapy in stroke patients	10
Determinants of willingness to pay for health services: a systematic review of contingent valuation studies	10
Survival analysis of cancer patients in Portugal following the reference centre model implementation	9
Assessment of health state utilities associated with adult and pediatric acid sphingomyelinase deficiency (ASMD)	9
Supply-side solutions targeting demand-side characteristics: causal effects of a chronic disease management program on adherence and health outcomes	9
Optimising the impact of COVID-19 vaccination on mortality and hospitalisations using an individual additive risk measuring approach based on a risk adjustment scheme	9
The ACA Medicaid expansions and abortion rates among young adults	9
Cost-effectiveness of two online interventions supporting self-care for eczema for parents/carers and young people	9
Self-interest, positional concerns and distributional considerations in healthcare preferences	9
Economics of hypothalamic obesity in patients with craniopharyngioma and other rare sellar/suprasellar tumors	8
Obtaining preference scores for an abbreviated self-completion version of the Teen-Addiction Severity Index (ASC T-ASI) to value therapy outcomes of systemic family interventions: a discrete choice ex	8
The link between physician motivation and care	8
Self vs. other, child vs. adult. An experimental comparison of valuation perspectives for valuation of EQ-5D-Y-3L health states	8
Does diagnostic testing always decrease antibiotics prescriptions?	8
Economic evaluation on dental caries preventive interventions for Australian children using a priority-setting approach	8
Healthcare costs of diabetic foot disease in Italy: estimates for event and state costs	8
The pass-through of excise taxes to market prices of heated tobacco products (HTPs) and cigarettes: a cross-country analysis	8
How are patient inputs considered in HTA? A thematic document analysis of NICE ultra-rare disease appraisals	8
Cost-utility of cochlear implantation in single-sided deafness and asymmetric hearing loss: results of a randomized controlled trial	8
Challenges for health systems seeking to embrace virtual health care for population health	8
Recovery of suspended reimbursements of high-cost drugs subjected to monitoring registries and negotiated agreements (MEAs): a tool for governance and clinical appropriateness in the Italian reality	8
Personnel shortages and the provision of long-term care: an empirical analysis of German nursing homes	8
Referring physicians' intention to use hospital report cards for hospital referral purposes in the presence or absence of patient-reported outcomes: a randomized trial	8
Examining the density in out-of-pocket spending share in the estimation of catastrophic health expenditures	7
Impact of the introduction of the AMNOG law on launch delays of new drugs in Germany: a comment	7
Modeling European health systems: a theoretical exercise	7
Assessing Taiwan’s pay-for-performance program for diabetes care: a cost–benefit net value approach	7
Unravelling heterogeneity in efficiency measurements: a case study of public hospitals in Spain	7
Cost-effectiveness evidence on approved cancer drugs in Ireland: the limits of data availability and implications for public accountability	7
Does health technology assessment compromise access to pharmaceuticals?	7
Trends and drivers of pharmaceutical expenditures from systemic anti-cancer therapy	7
Psychometric performance of proxy-reported EQ-5D youth version 5-level (EQ-5D-Y-5L) in comparison with three-level (EQ-5D-Y-3L) in children and adolescents with scoliosis	7
Disclosing the ‘Big C’: what does cancer survivorship signal to employers?	7
Seeking efficiency gains outside drugs and diagnostics	7
Generating EQ-5D-3L health utility scores from the Edinburgh Postnatal Depression Scale: a perinatal mapping study	7
The health and long-term care costs in the last year of life in The Netherlands	7
Inpatient care utilisation and expenditure associated with objective physical activity: econometric analysis of the UK Biobank	7
Estimating the additional costs of living with a disability in the United Kingdom between 2013 and 2016	7